US company announces results of an open phase II study of immunotherapy vaccines
US investment firm Key Capital Corporation (OTC: KCPC) announced that according to the Journal of Hepatocellular Carcinoma, an open phase II study of oral Hepko-V5 (hepcortespenlisimut-L) immunotherapy vaccine in 75 patients with advanced liver cancer showed that After 12 months of follow-up, the patient's survival rate has never reached 90%. The oral immunotherapy vaccine Hepko-V5 is safe and effective for patients with advanced liver cancer who cannot undergo surgery. Hepko-V5 is Immunitor Inc., a private biopharmaceutical company based in Vancouver, Canada. The product.
The study also showed that after 2 months of treatment, 50 of the 75 patients had a decrease in the liver tumor marker alpha-fetoprotein (AFP), suggesting that immunotherapy is effective in two-thirds of the study population. Because AFP reduction is associated with tumor shrinkage. When the AFP reaches a normal level, the tumor representing the patient is cleared and the patient is cured. A total of 12 patients (16%) had AFP eventually reaching a normal value below 10 IU/ml. In addition, according to observations, in the past 15 years, more than 10,000 patients with cirrhosis and hepatitis in more than 30 countries did not have any adverse reactions or poisoning after taking Hepko-V5.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bodybuildingoil.com